 |
市场调查报告书
商品编码
1629594
白细胞介素抑制剂市场：按类型、按给药途径、按应用、按分销管道、按地区Interleukin Inhibitors Market, By Type, By Route of Administration, By Application, By Distribution Channel, By Geography |
||||||
2024 年全球白细胞介素抑制剂市场规模估计为 326 亿美元，预计 2031 年将达到 748.1 亿美元，2024 年至 2031 年的复合年增长率为 12.6%。
| 报告范围 | 报告详细信息 | ||
|---|---|---|---|
| 基准年 | 2023 | 2024 年的市场规模 | 326亿美元 |
| 效能资料 | 2019 年至 2023 年 | 预测期 | 2024 年至 2031 年 |
| 预测期间 2024 年至 2031 年复合年增长率： | 12.60％ | 2031 年价值预测 | 748.1亿美元 |
白细胞介素抑制剂是阻断或减弱白细胞介素细胞激素活性的生技药品，白细胞介素细胞因子在引发发炎中发挥重要作用。这些蛋白质作为重要的讯号分子，引导白血球迁移到受伤或感染的部位。然而，过度或长期的发炎可能会导致问题。白细胞介素抑制剂针对特定的白细胞介素，有助于控制由不适当或过度的免疫反应引起的病症。它针对与自体免疫疾病相关的关键白细胞介素，包括 IL-17、IL-23 和 IL-1B。随着新型生技药品被核准用于治疗各种发炎和免疫介导疾病，全球白细胞介素抑制剂市场正在稳步增长。
市场动态：
全球白细胞介素抑制剂市场受到全球免疫相关疾病的增加和医疗保健支出的增加所推动。根据世界卫生组织估计，到2024年11月，全球约有2-3%的人口将患有自体免疫疾病，其中许多病例未诊断或治疗。新型白细胞介素抑制剂核准用于治疗干干癣性关节炎、僵直性脊椎炎、溃疡性大肠炎等尚未满足医疗需求的疾病，也推动了市场的成长。然而，生技药品的高成本对于价格敏感的新兴市场的市场扩张构成了重大挑战。此外，重磅药物的专利悬崖进一步加剧了竞争。也就是说，正在进行的研究和开发具有更安全性和新治疗适应症的白细胞介素介素抑制剂为市场上的公司提供了有吸引力的机会。
本研究的主要特点
本报告对全球白细胞介素抑制剂市场进行了详细分析，并以 2023 年为基准年，展示了预测期（2024-2031 年）的市场规模和年复合成长率（CAGR%）。
它还强调了各个领域的潜在商机，并说明了该市场的引人注目的投资提案矩阵。
它还提供了关于市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的主要考察。
全球白细胞介素抑制剂市场的主要企业根据公司亮点、产品系列、关键亮点、性能和策略等参数进行分析。
研究涉及的主要企业包括 AbbVie Inc.、强生公司、安进公司、诺华公司、赛诺菲公司、葛兰素史克公司、礼来公司、再生元製药公司、默克公司、武田製药有限公司、Biogen Inc.、UCB SA、安斯泰来製药公司、拜耳公司和山德士国际有限公司。
本报告的见解将帮助负责人和企业经营团队就未来产品发布、高端市场策略、市场扩张和行销策略做出明智的决策。
本研究报告针对该产业的各个相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
相关人员将透过分析全球白细胞介素抑制剂市场所使用的各种策略矩阵更轻鬆地做出决策。
目录
第一章 调查目的与前提条件
- 研究目标
- 先决条件
- 简称
第二章 市场展望
- 报告描述
- 市场定义和范围
- 执行摘要
第三章市场动态、法规与趋势分析
- 市场动态
- 影响分析
- 主要进展
- 监管情景
- 产品发布/核准
- PEST分析
- PORTER 分析
- 併购情景
- 产业趋势
4. 全球白细胞介素抑制剂市场，依类型，2019-2031 年
- IL-1 抑制剂
- IL-5 抑制剂
- IL-6 抑制剂
- IL-17 抑制剂
- IL-23 抑制剂
- 其他类型
5. 全球白细胞介素抑制剂市场，依给药途径，2019-2031 年
- 口服
- 皮下（SC）
- 静脉注射 (IV)
- 其他的
6. 全球白细胞介素抑制剂市场，依应用，2019-2031 年
- 类风湿性关节炎
- 干癣性关节炎
- 干癣
- 发炎性肠道疾病(IBD)
- 气喘
- 多发性硬化症
- 溃疡性大肠炎
- 克隆氏症
- 其他用途
7. 全球白细胞介素抑制剂市场，按分销管道，2019-2031 年
- 医院药房
- 零售药局
- 网路药局
8. 全球白细胞介素抑制剂市场，按地区，2019-2031 年
- 北美洲
- 拉丁美洲
- 欧洲
- 亚太地区
- 中东
- 非洲
第九章 竞争格局
- AbbVie Inc.
- Johnson & Johnson
- Amgen Inc.
- Novartis AG
- Sanofi SA
- GSK plc
- Eli Lilly and Company
- Regeneron Pharmaceuticals, Inc.
- Merck & Co., Inc.
- Takeda Pharmaceutical Company Limited
- Biogen Inc.
- UCB SA
- Astellas Pharma Inc.
- Bayer AG
- Sandoz International GmbH
第 10 章分析师建议
- 命运之轮
- 分析师观点
- 一致的机会图
第 11 章 参考文献与调查方法
- 参考
- 调查方法
- 关于出版商
The global interleukin inhibitors market is estimated to be valued at USD 32.60 Bn in 2024 and is expected to reach USD 74.81 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 12.6% from 2024 to 2031.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2023 | Market Size in 2024: | US$ 32.60 Bn |
| Historical Data for: | 2019 To 2023 | Forecast Period: | 2024 To 2031 |
| Forecast Period 2024 to 2031 CAGR: | 12.60% | 2031 Value Projection: | US$ 74.81 Bn |
Interleukin inhibitors are biologics that block or dampen the activity of interleukin cytokines that play important roles in triggering inflammation. These proteins act as signaling molecules that are critical in directing the movement of white blood cells to sites of injury or infection. However, excess or prolonged inflammation can cause issues. Interleukin inhibitors help control conditions driven by inappropriate or excessive immune responses by targeting specific interleukins. Some key interleukin targets include IL-17, IL-23, and IL-1B that are implicated in autoimmune diseases. The global interleukin inhibitors market has been growing steadily as new biologics gain regulatory approvals for treating various inflammatory and immune-mediated disorders.
Market Dynamics:
The global interleukin inhibitors market is driven by the increasing prevalence of immune-mediated conditions worldwide coupled with rising healthcare expenditures. In November 2024, according to the WHO estimates, around 2-3% of the global population suffers from autoimmune diseases with many cases remaining undiagnosed or untreated. Approvals of novel interleukin inhibitors for treating diseases with high unmet needs such as psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis are also boosting the market growth. However, high costs of biologics pose a major challenge for market expansion in price-sensitive developing regions. Moreover, patent cliffs of blockbuster drugs further intensify competition. Nevertheless, ongoing R&D for developing interleukin inhibitors with improved safety profiles and new therapeutic indications provide attractive opportunities for market players.
Key Features of the Study:
This report provides in-depth analysis of the global interleukin inhibitors market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global interleukin inhibitors market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include AbbVie Inc., Johnson & Johnson, Amgen Inc., Novartis AG, Sanofi S.A., GSK plc, Eli Lilly and Company, Regeneron Pharmaceuticals, Inc., Merck & Co., Inc., Takeda Pharmaceutical Company Limited, Biogen Inc., UCB S.A., Astellas Pharma Inc., Bayer AG, and Sandoz International GmbH
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global interleukin inhibitors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global interleukin inhibitors market
Market Segmentation
- By Type Insights (Revenue, USD Bn, 2019 - 2031)
- IL-1 inhibitors
- IL-5 inhibitors
- IL-6 inhibitors
- IL-17 inhibitors
- IL-23 inhibitors
- Other types
- By Route of Administration Insights (Revenue, USD Bn, 2019 - 2031)
- Oral
- Subcutaneous (SC)
- Intravenous (IV)
- Others
- By Application Insights (Revenue, USD Bn, 2019 - 2031)
- Rheumatoid arthritis
- Psoriatic arthritis
- Psoriasis
- Inflammatory bowel disease (IBD)
- Asthma
- Multiple Sclerosis
- Ulcerative colitis
- Crohn's disease
- Other applications
- By Distribution Channel Insights (Revenue, USD Bn, 2019 - 2031)
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
- Regional Insights (Revenue, USD Bn, 2019 - 2031)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- AbbVie Inc.
- Johnson & Johnson
- Amgen Inc.
- Novartis AG
- Sanofi S.A.
- GSK plc
- Eli Lilly and Company
- Regeneron Pharmaceuticals, Inc.
- Merck & Co., Inc.
- Takeda Pharmaceutical Company Limited
- Biogen Inc.
- UCB S.A.
- Astellas Pharma Inc.
- Bayer AG
- Sandoz International GmbH
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Interleukin Inhibitors Market, By Type
- Global Interleukin Inhibitors Market, By Route of Administration
- Global Interleukin Inhibitors Market, By Application
- Global Interleukin Inhibitors Market, By Distribution Channel
- Global Interleukin Inhibitors Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Interleukin Inhibitors Market, By Type, 2019-2031, (USD Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- IL-1 inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- IL-5 inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- IL-6 inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- IL-17 inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- IL-23 inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Other types
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
5. Global Interleukin Inhibitors Market, By Route of Administration, 2019-2031, (USD Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Subcutaneous (SC)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Intravenous (IV)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
6. Global Interleukin Inhibitors Market, By Application, 2019-2031, (USD Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Rheumatoid arthritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Psoriatic arthritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Psoriasis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Inflammatory bowel disease (IBD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Asthma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Multiple Sclerosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Ulcerative colitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Crohn's disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Other applications
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
7. Global Interleukin Inhibitors Market, By Distribution Channel, 2019-2031, (USD Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Hospital pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Retail pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Online pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
8. Global Interleukin Inhibitors Market, By Region, 2019 - 2031, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2024,2027 & 2031, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2020 - 2031, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Application, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Application, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Application, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Application, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Application, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Application, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2019 - 2031, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
9. Competitive landscape
- AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Sanofi S.A.
- GSK plc
- Eli Lilly and Company
- Regeneron Pharmaceuticals, Inc.
- Merck & Co., Inc.
- Takeda Pharmaceutical Company Limited
- Biogen Inc.
- UCB S.A.
- Astellas Pharma Inc.
- Bayer AG
- Sandoz International GmbH
10. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
11. References and Research Methodology
- References
- Research Methodology
- About us
